Paresh Vyas

Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy.

Turkalj S. et al, (2026), Blood, 147, 613 - 632

LIDHE phase 3b study design: ivosidenib + azacitidine in adults with newly diagnosed IDH1 mutant acute myeloid leukemia.

Vyas P. et al, (2025), Future Oncol, 21, 3721 - 3729

Patient involvement in the design of ALIDHE: a study of ivosidenib + azacitidine in newly diagnosed IDH1 mutant AML.

Nier S. et al, (2025), Future Oncol, 21, 3713 - 3719

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2025)

Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2025)

Clinical significance of preleukemic somatic GATA1 mutations in children with Down syndrome.

Elliott N. et al, (2025), Blood, 146, 1561 - 1574

Genome-wide association study of somatic GATA1s mutations in newborns with Down syndrome.

Li Y. et al, (2025), Blood Adv, 9, 4235 - 4243

evised prognostic model for patients with acute myeloid leukemia and first relapse.

van der Maas NG. et al, (2025), Blood Adv, 9, 3853 - 3864

Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.

Zeidner JF. et al, (2025), Blood, 146, 590 - 600

The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy.

Daver N. et al, (2025), Blood, 146, 601 - 611

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2025)

Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2025)

Clonal tracing with somatic epimutations reveals dynamics of blood ageing.

Scherer M. et al, (2025), Nature, 643, 478 - 487

Detecting and quantifying clonal selection in somatic stem cells.

Körber V. et al, (2025), Nat Genet, 57, 1718 - 1729

Protocol for high-quality RNA sequencing, cell surface protein analysis, and genotyping in single cells using TARGET-seq.

Jakobsen NA. et al, (2025), STAR Protoc, 6

Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation.

Hosseini A. et al, (2025), Nature, 642, 508 - 518

Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia.

Mannis GN. et al, (2025), EJHaem, 6

Microbial metabolite drives ageing-related clonal haematopoiesis via ALPK1.

Agarwal P. et al, (2025), Nature, 642, 201 - 211

Genome-Wide Association Studies of Down Syndrome Associated Congenital Heart Defects Suggests a Genetically Heterogeneous Risk for CHD in DS.

Feldman ER. et al, (2025), Genet Epidemiol, 49

Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.

Russell NH. et al, (2025), J Clin Oncol, 43, 694 - 704

Fetal Liver-Restricted Leukemic Proliferation Via GATA1s-CSF2RB-MPL Axis In Down Syndrome

Vyas P. et al, (2025)

Risk Stratification in Older Intensively Treated Patients With AML.

Versluis J. et al, (2024), J Clin Oncol, 42, 4084 - 4094

Supplementary Protocol from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies

Lachowiez CA. et al, (2024)

Supplementary Tables and Figures from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies

Lachowiez CA. et al, (2024)

Supplementary Tables and Figures from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies

Lachowiez CA. et al, (2024)

Supplementary Protocol from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies

Lachowiez CA. et al, (2024)

Genome-wide association studies of Down syndrome associated congenital heart defects.

Feldman ER. et al, (2024)

Hematopoietic stem cell heterogeneity and age-associated platelet bias are evolutionarily conserved.

Aksöz M. et al, (2024), Sci Immunol, 9

Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging.

Jakobsen NA. et al, (2024), Cell Stem Cell, 31, 1127 - 1144.e17

Lead optimisation of OXS007417: in vivo PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia.

Cogswell TJ. et al, (2024), RSC Med Chem, 15, 3495 - 3506

Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.

Risueño A. et al, (2024), Leuk Res, 140

Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.

Rajakumaraswamy N. et al, (2024), Clin Lymphoma Myeloma Leuk, 24, 260 - 268.e2

HDAC inhibitor derivatives induce differentiation of leukemic cells through two distinct and separable mechanisms

Kumar P. et al, (2024)

Clonal Basis of Resistance and Response to Ivosidenib Combination Therapies Is Established Early during Treatment in IDH1-Mutated Myeloid Malignancies

Turkalj S. et al, (2024), BLOOD, 144, 642 - 644

protocol for simultaneous high-sensitivity genotyping and chromatin accessibility profiling in single cells.

Turkalj S. et al, (2023), STAR Protoc, 4

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.

Freeman SD. et al, (2023), Blood, 142, 1697 - 1707

Changing treatment changing prognosis of mutations.

Vyas P., (2023), Blood, 142, 1583 - 1585

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.

Daver NG. et al, (2023), J Clin Oncol, 41, 4893 - 4904

Phenotypic screening identifies a trisubstituted imidazo[1,2-a]pyridine series that induces differentiation in multiple AML cell lines.

Josa-Culleré L. et al, (2023), Eur J Med Chem, 258

Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.

Lachowiez CA. et al, (2023), Blood Cancer Discov, 4, 276 - 293

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Data from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Data from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Data from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

n Overview of Targeted Therapies in Acute Myeloid Leukemia.

Turkalj S. et al, (2023), Hemasphere, 7

Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.

Sallman DA. et al, (2023), J Clin Oncol, 41, 2815 - 2826

GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells.

Turkalj S. et al, (2023), Cell Stem Cell, 30, 722 - 740.e11

Correction: Pan-cancer analysis of whole genomes.

ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium ., (2023), Nature, 614

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.

de Botton S. et al, (2023), Blood, 141, 156 - 167

Dysregulation of chromatin via H3K27 methylation underpins differentiation arrest in Isocitrate dehydrogenase-mutant Acute Myeloid Leukaemia

Silveira DRA. et al, (2023)

Selective advantage of mutant stem cells in clonal hematopoiesis occurs by attenuating the deleterious effects of inflammation and aging

Jakobsen NA. et al, (2023)

Sustained MYB Activity Is Necessary for Oncogenic Transcription in KMT2A-Rearranged Acute Lymphoblastic Leukemia through Enhancer-Promoter Interactions and Epigenetic Modifications at Enhancers

Lau J. et al, (2023), BLOOD, 142

Correction: Divergent mutational processes distinguish hypoxic and normoxic tumours.

Bhandari V. et al, (2022), Nat Commun, 13

Correction: Pathway and network analysis of more than 2500 whole cancer genomes.

Reyna MA. et al, (2022), Nat Commun, 13

Correction: Combined burden and functional impact tests for cancer driver discovery using DriverPower.

Shuai S. et al, (2022), Nat Commun, 13

Correction: Inferring structural variant cancer cell fraction.

Cmero M. et al, (2022), Nat Commun, 13

Correction: Divergent mutational processes distinguish hypoxic and normoxic tumours.

Bhandari V. et al, (2022), Nat Commun, 13

Correction: High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations.

Zhang Y. et al, (2022), Nat Commun, 13

Correction: A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns.

Jiao W. et al, (2022), Nat Commun, 13

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.

Daver NG. et al, (2022), Cancer Discov, 12, 2516 - 2529

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma.

Gooding S. et al, (2022), Blood, 140, 1816 - 1821

MDS-482 Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS).

Chen J. et al, (2022), Clin Lymphoma Myeloma Leuk, 22 Suppl 2, S317 - S318

Phase Ib study of eltrombopag and azacitidine in patients with high-risk myelodysplastic syndromes and related disorders (the ELASTIC study).

Sternberg A. et al, (2022), Br J Haematol, 199, 222 - 229

ML-348 A Phase Ib/II Study of Ivosidenib With Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies

Lachowiez C. et al, (2022), Clinical Lymphoma, Myeloma and Leukemia, 22, S240 - S241

ML-464 Tolerability and Efficacy of the First-In-Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia (AML): Phase 1b Results

Daver N. et al, (2022), Clinical Lymphoma, Myeloma and Leukemia, 22, S253 - S254

ML-399 A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined With Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia (AML)

Vyas P. et al, (2022), Clinical Lymphoma, Myeloma and Leukemia, 22

ML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions

Daver N. et al, (2022), Clinical Lymphoma, Myeloma and Leukemia, 22, S231 - S232

ML-432 Overall Survival (OS) by IDH2 Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant-IDH2 Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial

DiNardo CD. et al, (2022), Clinical Lymphoma, Myeloma and Leukemia, 22, S249 - S250

MDS-445 Magrolimab In Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results

Sallman D. et al, (2022), Clinical Lymphoma, Myeloma and Leukemia, 22, S314 - S315

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.

Arber DA. et al, (2022), Blood, 140, 1200 - 1228

bulin binding molecule drives differentiation of acute myeloid leukemia cells.

Jackson TR. et al, (2022), iScience, 25

phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.

Sekeres MA. et al, (2022), Ann Hematol, 101, 1689 - 1701

Heterogeneous genetic and non-genetic mechanisms contribute to response and resistance to azacitidine monotherapy.

Symeonidou V. et al, (2022), EJHaem, 3, 794 - 803

Shall We Dance: Evolving Partnerships of Targeted Therapies for AML.

Perl AE. and Vyas P., (2022), Clin Cancer Res, 28, 2719 - 2721

Genetic and non-genetic mechanisms of inflammation may promote transformation in leukemia.

Vyas P., (2022), Cell Stem Cell, 29, 184 - 186

Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy.

Loke J. et al, (2022), Br J Haematol, 196, 368 - 373

Mutation agnostic diagnosis of clonal hematopoiesis of indeterminate potential (CHIP) using fluctuating methylation clocks

Schenck RO. et al, (2022), CANCER RESEARCH, 82

Phase 3, Randomized Trial of Magrolimab in Combination With Venetoclax and Azacitidine in Previously Untreated Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy (ENHANCE-3)

Daver N. et al, (2022), AMERICAN JOURNAL OF HEMATOLOGY, 97, S5 - S5

Magrolimab in Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes: 5F9005 Phase 1b Study Results

Sallman DA. et al, (2022), AMERICAN JOURNAL OF HEMATOLOGY, 97, S20 - S21

Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine in Previously Untreated Patients With TP53-Mutant Acute Myeloid Leukemia

Daver N. et al, (2022), AMERICAN JOURNAL OF HEMATOLOGY, 97, S5 - S6

Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathways.

Ortiz-Estévez M. et al, (2021), BMC Med Genomics, 14

Phenotypic Screen Identifies a Compound Series That Induces Differentiation of Acute Myeloid Leukemia Cells In Vitro and Shows Antitumor Effects In Vivo.

Josa-Culleré L. et al, (2021), J Med Chem, 64, 15608 - 15628

Identification and Preliminary Structure-Activity Relationship Studies of 1,5-Dihydrobenzo[e][1,4]oxazepin-2(3H)-ones That Induce Differentiation of Acute Myeloid Leukemia Cells In Vitro.

Josa-Culleré L. et al, (2021), Molecules, 26

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.

DiNardo CD. et al, (2021), Lancet Oncol, 22, 1597 - 1608

bstracts from the 2021 Lymphoma and Myeloma Congress October 19-23, 2021.

(2021), Am J Hematol, 96 Suppl 1, S3 - S33

Sowing the seeds of leukemia before birth.

Roberts I. and Vyas P., (2021), Science, 373, 155 - 156

andomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.

Dennis M. et al, (2021), Br J Haematol, 194, 298 - 308

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome.

Hoeks M. et al, (2021), Leukemia, 35, 1745 - 1750

Malcovati L, Stevenson K, Papaemmanuil E, et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood. 2020;136(2):157-170.

(2021), Blood, 137

Chromatin accessibility governs the differential response of cancer and T cells to arginine starvation.

Crump NT. et al, (2021), Cell Rep, 35

Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes.

Garcia-Manero G. et al, (2021), J Clin Oncol, 39, 1426 - 1436

Oncogenic Gata1 causes stage-specific megakaryocyte differentiation delay.

Juban G. et al, (2021), Haematologica, 106, 1106 - 1119

Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia.

Hashimoto M. et al, (2021), Nat Cancer, 2, 340 - 356

Poorer Clinical Outcomes for Black Patients with AML: A Wake-Up Call for Better Data and Greater Understanding of Cancer Outcomes in All Ethnic Groups.

Vyas P., (2021), Cancer Discov, 11, 540 - 541

Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia.

Hashimoto M. et al, (2021), Nat Cancer, 2, 340 - 356

The genome-wide impact of trisomy 21 on DNA methylation and its implications for hematopoiesis.

Muskens IS. et al, (2021), Nat Commun, 12

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma.

Gooding S. et al, (2021), Blood, 137, 232 - 237

Poorer Clinical Outcomes For Black Patients With AML: A Wake Up Call For Better Data And Greater Understanding Of Cancer Outcomes In All Ethnic Groups

VYAS P., (2021), Cancer Discovery

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.

DiNardo CD. et al, (2021), J Clin Oncol, 39, 57 - 65

multicenter comparative acute myeloid leukemia study: can we explain the differences in the outcomes in resource-constrained settings?

Silveira DRA. et al, (2021), Leuk Lymphoma, 62, 147 - 157

H3K79me2/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells.

Godfrey L. et al, (2021), Leukemia, 35, 90 - 106

Integrative multi-omics identifies high risk Multiple Myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathways

Ortiz-Estévez M. et al, (2021)

lternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: A meta-analysis and systematic review (Russian Translation of Cochrane Plain Language Summary)

Desborough MJR. et al, (2021), Journal of Modern Oncology, 23, 635 - 636

Outcomes for Patients with Late-Stage Mutant-IDH2 (m IDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial

DiNardo CD. et al, (2021), BLOOD, 138

Magrolimab plus azacitidine versus azacitidine plus placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): The phase 3, randomized, ENHANCE study.

Garcia-Manero G. et al, (2021), JOURNAL OF CLINICAL ONCOLOGY, 39

PHASE 3 STUDY OF ENASIDENIB (ENA) VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH LATE-STAGE MUTANT-IDH2 (MIDH2) RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML)

Papayannidis C. et al, (2021), HAEMATOLOGICA, 106, 1 - 1

Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine in Previously Untreated Patients with TP53-Mutant Acute Myeloid Leukemia

Daver N. et al, (2021), BLOOD, 138

Magrolimab plus Azacitidine Versus Azacitidine plus Placebo in Untreated Higher-Risk (HR) Myelodysplastic Syndromes (MDS): The Phase 3, Randomized, ENHANCE Study

Garcia-Manero G. et al, (2021), CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 21, S343 - S344

Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (m IDH2) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC)

DiNardo CD. et al, (2021), BLOOD, 138

Repressed Chromatin Drives Leukaemogenesis in Mutant IDH2 Acute Myeloid Leukaemia Via Inhibition of Granulocyte Differentiation and Cell Cycle Progression

Silveira DRA. et al, (2021), BLOOD, 138

phase Ib/II study of ivosidenib with venetoclax plus /- azacitidine in IDH1-mutated myeloid malignancies.

Lachowiez CA. et al, (2021), JOURNAL OF CLINICAL ONCOLOGY, 39

Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined with Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia

Vyas P. et al, (2021), BLOOD, 138

The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results

Sallman D. et al, (2021), CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 21, S290 - S290

The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results

Sallman D. et al, (2021), CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 21, S290 - S290

Disease Models & Mechanisms announces a new Editor-in-Chief.

Vyas P., (2020), Dis Model Mech, 13

Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review.

Cortes JE. et al, (2020), Leuk Lymphoma, 61, 3287 - 3305

Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples.

Bailey MH. et al, (2020), Nat Commun, 11

New directions for emerging therapies in acute myeloid leukemia: the next chapter.

Daver N. et al, (2020), Blood Cancer J, 10

BCL-2 Inhibitor and Conventional Chemotherapy Combinations for Acute Myeloid Leukemia: Shifting From the Unfit to the Fit Patient With AML.

Ossenkoppele G. and Vyas P., (2020), J Clin Oncol, 38, 3461 - 3464

Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples.

Bailey MH. et al, (2020), Nat Commun, 11

Sensitive, rapid diagnostic test for transient abnormal myelopoiesis and myeloid leukemia of Down syndrome.

Cruz Hernandez D. et al, (2020), Blood, 136, 1460 - 1465

pplicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting.

Hanekamp D. et al, (2020), Br J Haematol, 190, 891 - 900

Mechanisms of Response and Resistance to AML Therapies.

Stoilova B. et al, (2020), Clin Lymphoma Myeloma Leuk, 20 Suppl 1

SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications.

Singh S. et al, (2020), Leukemia, 34, 2525 - 2530

Sex differences in oncogenic mutational processes.

Li CH. et al, (2020), Nat Commun, 11

Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers.

Fagnan A. et al, (2020), Blood, 136, 698 - 714

Multiple Cereblon genetic changes associate with acquired resistance to Lenalidomide or Pomalidomide in Multiple Myeloma.

Gooding S. et al, (2020), Blood

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts.

Zeidan AM. et al, (2020), Lancet Haematol, 7, e601 - e612

Identification of 2 DNA methylation subtypes of Waldenström macroglobulinemia with plasma and memory B-cell features.

Roos-Weil D. et al, (2020), Blood, 136, 585 - 595

SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.

Malcovati L. et al, (2020), Blood, 136, 157 - 170

Myeloid Pre-Leukemia and Leukemia of Down Syndrome

Cruz Hernandez D. and VYAS P., (2020), HemaSphere

Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia.

Silveira DRA. et al, (2020), Blood Adv, 4, 2339 - 2350

C/EBPα and GATA-2 Mutations Induce Bilineage Acute Erythroid Leukemia through Transformation of a Neomorphic Neutrophil-Erythroid Progenitor.

Di Genua C. et al, (2020), Cancer Cell, 37, 690 - 704.e8

Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial.

Angelucci E. et al, (2020), Ann Intern Med, 172, 513 - 522

Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial.

Stanworth SJ. et al, (2020), Br J Haematol, 189, 279 - 290

Transient abnormal myelopoiesis without constitutional Down syndrome

Kairiene I. et al, (2020), Journal of Pediatric and Neonatal Individualized Medicine, 9

shared somatic translocation involving CUX1 in monozygotic twins as an early driver of AMKL in Down syndrome.

Bache I. et al, (2020), Blood Cancer J, 10

Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition.

Rodriguez-Martin B. et al, (2020), Nat Genet, 52, 306 - 319

Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing.

Cortés-Ciriano I. et al, (2020), Nat Genet, 52, 331 - 341

The landscape of viral associations in human cancers.

Zapatka M. et al, (2020), Nat Genet, 52, 320 - 330

Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer.

Akdemir KC. et al, (2020), Nat Genet, 52, 294 - 305

Comprehensive molecular characterization of mitochondrial genomes in human cancers.

Yuan Y. et al, (2020), Nat Genet, 52, 342 - 352

Pathway and network analysis of more than 2500 whole cancer genomes.

Reyna MA. et al, (2020), Nat Commun, 11

Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig.

Rubanova Y. et al, (2020), Nat Commun, 11

Patterns of somatic structural variation in human cancer genomes.

Li Y. et al, (2020), Nature, 578, 112 - 121

Genomic basis for RNA alterations in cancer.

PCAWG Transcriptome Core Group . et al, (2020), Nature, 578, 129 - 136

Pan-cancer analysis of whole genomes.

ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium ., (2020), Nature, 578, 82 - 93

nalyses of non-coding somatic drivers in 2,658 cancer whole genomes.

Rheinbay E. et al, (2020), Nature, 578, 102 - 111

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.

Fenaux P. et al, (2020), N Engl J Med, 382, 140 - 151

GATA1 and cooperating mutations in myeloid leukaemia of Down syndrome.

Garnett C. et al, (2020), IUBMB Life, 72, 119 - 130

Oncogenic Drivers and Development.

Cruz Hernandez D. and Vyas P., (2019), Cancer Discov, 9, 1653 - 1655

Cellular and molecular basis of haematopoiesis

VYAS P. and JAKOBSEN N., (2019)

Discovery of a CD10-negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programs.

O'Byrne S. et al, (2019), Blood, 134, 1059 - 1071

Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.

Labuhn M. et al, (2019), Cancer Cell, 36

Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.

Labuhn M. et al, (2019), Cancer Cell, 36, 123 - 138.e10

The Inflammasome: More Than a Protective Innate Immune Mechanism.

Stoilova B. and Vyas P., (2019), Immunity, 51, 3 - 5

The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia.

Brierley CK. et al, (2019), Transfusion, 59, 2248 - 2254

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Haase D. et al, (2019), Leukemia, 33, 1747 - 1758

DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation.

Godfrey L. et al, (2019), Nat Commun, 10

Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation.

Roos-Weil D. et al, (2019), Cancer Discov, 9, 796 - 811

Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia.

Marquis M. et al, (2019), Blood Cancer J, 9

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.

Stein EM. et al, (2019), Blood, 133, 676 - 687

CUTE LEUKEMIAS XVII Biology and Treatment Strategies.

(2019), Ann Hematol, 98, 1 - 75

The Graft-Versus-Leukemia Effect in AML.

Sweeney C. and Vyas P., (2019), Front Oncol, 9

OncogenicGata1causes stage-specific megakaryocyte differentiation delay

Juban G. et al, (2019)

Most haematological abnormalities in neonates with Down syndrome are transient but dysplastic myelopoiesis persists throughout early childhood

Hanssen L. et al, (2019), BRITISH JOURNAL OF HAEMATOLOGY, 185, 106 - 106

zacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia.

Dickinson M. et al, (2018), Blood, 132, 2629 - 2638

SCL/TAL1 cooperates with Polycomb RYBP-PRC1 to suppress alternative lineages in blood-fated cells.

Chagraoui H. et al, (2018), Nat Commun, 9

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care.

Döhner H. et al, (2018), Leukemia, 32, 2546 - 2557

enuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial.

Russell N. et al, (2018), Blood, 132, 1452 - 1454

Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.

Pellagatti A. et al, (2018), Blood, 132, 1225 - 1240

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.

Quek L. et al, (2018), Nat Med, 24, 1167 - 1177

High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia.

Marquis M. et al, (2018), Blood Cancer J, 8

Guidelines for the investigation and management of Transient Leukaemia of Down Syndrome.

Tunstall O. et al, (2018), Br J Haematol, 182, 200 - 211

Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia.

Craddock C. et al, (2018), J Intern Med, 283, 371 - 379

From genomics to targeted treatment in haematological malignancies: a focus on acute myeloid leukaemia.

Jakobsen NA. and Vyas P., (2018), Clin Med (Lond), 18, s47 - s53

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

Schuurhuis GJ. et al, (2018), Blood, 131, 1275 - 1291

Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells.

Karamitros D. et al, (2018), Nat Immunol, 19, 85 - 97

DOT1L inhibition reveals a distinct class of enhancers dependent on H3K79 methylation

Godfrey L. et al, (2018)

Color Atlas Of Clinical Hematology: Molecular and Cellular Basis of Disease

Hoffbrand AV. et al, (2018), 1 - 585

Single Cell Analysis of Acquired Pomalidomide-Resistance in Multiple Myeloma Cell Lines Reveals Distinct Subclonal Cereblon Mutations and Gene Expression Heterogeneity

Gooding S. et al, (2018), BLOOD, 132

RBC-Specific CD47 Pruning Confers Protection and Underlies the Transient Anemia in Patients Treated with Anti-CD47 Antibody 5F9

Chen JY. et al, (2018), BLOOD, 132

Outcomes of Relapsed/Refractory Patients with IDH1/2 Mutated AML Treated with Non-Targeted Therapy: Results from the NCRI AML Trials

Hills RK. et al, (2018), BLOOD, 132

Results of a Phase 2 Trial of the Monocyte-Targeted Histone Deacetylase Inhibitor Tefinostat (CHR-2845) in Chronic Myelomonocytic Leukemia (CMML) - the UK Monocle Study

Knapper S. et al, (2018), BLOOD, 132

Therapy-Related Myeloid Neoplasms with Balanced Chromosome Rearrangements Frequently Arise from Pre-Existing Clonal Haematopoiesis

Dillon R. et al, (2018), BLOOD, 132

Modelling the Progression of a Preleukemic Stage to Overt Leukemia in Children with Down Syndrome

Labuhn M. et al, (2018), BLOOD, 132

Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature.

Craddock CF. et al, (2017), Clin Cancer Res, 23, 6430 - 6440

Editing an α-globin enhancer in primary human hematopoietic stem cells as a treatment for β-thalassemia.

Mettananda S. et al, (2017), Nat Commun, 8

The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes.

Yip BH. et al, (2017), J Clin Invest, 127

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Stein EM. et al, (2017), Blood, 130, 722 - 731

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.

Amatangelo MD. et al, (2017), Blood, 130, 732 - 741

The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes.

Yip BH. et al, (2017), J Clin Invest, 127, 2206 - 2221

Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia.

Giustacchini A. et al, (2017), Nat Med, 23, 692 - 702

CUTE LEUKEMIAS XVI.

(2017), Ann Hematol, 96, 1 - 89

ZACITIDINE PROLONGSOVERALL SURVIVAL IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WITH POOR PROGNOSTIC KARYOTYPES

Doehner H. et al, (2017), LEUKEMIA RESEARCH, 55, S70 - S71

Novel Model of Human Hemopoiesis Based on Single Cell Functional and Transcriptional Analysis of Lympho-Myeloid Progenitors

Stoilova B. et al, (2017), BLOOD, 130

FIRST-IN-CLASS, ORAL MUTANT IDH2 INHIBITOR REVERSES DIFFERENTIATION BLOCK IN ACUTE MYELOID LEUKAEMIA TO PRODUCE CLINICALLY MEANINGFUL RESPONSES

Vyas P., (2017), EXPERIMENTAL HEMATOLOGY, 53, S38 - S38

Clonal Heterogeneity in Differentiation Response and Resistance to the IDH2 Inhibitor Enasidenib in Acute Myeloid Leukemia

Quek L. et al, (2017), BLOOD, 130

SINGLE CELL ASSAYS UNVEIL FUNCTIONAL AND TRANSCRIPTIONAL HETEROGENEITY OF HUMAN HEMOPOIETIC LYMPHO-MYELOID PROGENITORS

Stoilova B. et al, (2017), EXPERIMENTAL HEMATOLOGY, 53, S50 - S50

IDENTIFICATION OF ABERRANTLY SPLICED GENES AND DEREGULATED PATHWAYS/GENE ONTOLOGY THEMES IN MYELODYSPLASTIC SYNDROME PATIENTS WITH SPLICING FACTOR GENE MUTATIONS

Pellagatti A. et al, (2017), HAEMATOLOGICA, 102, 12 - 12

NOVEL MODEL OF HUMAN LYMPHO-MYELOID PROGENITOR HIERARCHY BASED ON SINGLE CELL FUNCTIONAL AND TRANSCRIPTIONAL ANALYSIS

Karamitros D. et al, (2017), HAEMATOLOGICA, 102, 20 - 20

IDENTIFICATION OF ABERRANT SPLICING EVENTS IN MYELODYSPLASTIC SYNDROME PATIENTS WITH SPLICING FACTOR GENE MUTATIONS

Pellagatti A. et al, (2017), LEUKEMIA RESEARCH, 55, S9 - S9

nalysis of arginine metabolism in acute myeloid leukaemia to provide insights into tumour immune escape strategies

Hadjinicolaou AV. et al, (2017), LANCET, 389, 42 - 42

MOLECULAR PREDICTORS OF RESPONSE TO AZACITIDINE THERAPY: THE RESULTS OF THE UK TRIALS ACCELERATION PROGRAMME RAVVA STUDY

Craddock C. et al, (2017), HAEMATOLOGICA, 102, 323 - 323

NEXT GENERATION SEQUENCING TECHNIQUES REVEAL MOLECULAR MECHANISMS OF MYB REGULATION AND FUNCTION IN MLL-AF9 LEUKEMIA

Lau I-J. et al, (2017), HAEMATOLOGICA, 102, 207 - 207

Impact of Mutant Haemopoietic Transcription Factor GATA1s on Haemopoiesis

Vyas P. et al, (2017), BLOOD, 130

Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia.

Quek L. et al, (2016), Blood Adv, 1, 193 - 204

Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia.

Kinstrie R. et al, (2016), Blood Adv, 1, 160 - 169

n operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation.

Ferguson P. et al, (2016), Haematologica, 101, 1351 - 1358

lternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review.

Desborough M. et al, (2016), Cochrane Database Syst Rev, 10

Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update.

Bhatnagar N. et al, (2016), Curr Hematol Malig Rep, 11, 333 - 341

Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.

Quek L. et al, (2016), J Exp Med, 213, 1513 - 1535

G371 Defining transient abnormal myelopoiesis (TAM) and silent tam in neonates with down syndrome

Bhatnagar N. et al, (2016), Archives of Disease in Childhood, 101, A217.1 - A217

The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias.

Zabkiewicz J. et al, (2016), Oncotarget, 7, 16650 - 16662

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.

Andreeff M. et al, (2016), Clin Cancer Res, 22, 868 - 876

ssessment of Minimal Residual Disease in Standard-Risk AML.

Ivey A. et al, (2016), N Engl J Med, 374, 422 - 433

Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial.

Craddock C. et al, (2016), Biol Blood Marrow Transplant, 22, 385 - 390

lternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with thrombocytopenia due to chronic bone marrow failure: a network meta-analysis and systematic review.

Desborough M. et al, (2016), Cochrane Database Syst Rev, 2016

Prenatal therapy in transient abnormal myelopoiesis: a systematic review.

Tamblyn JA. et al, (2016), Arch Dis Child Fetal Neonatal Ed, 101, F67 - F71

Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia.

Khan N. et al, (2016), PLoS One, 11

SCL ESTABLISHES A TRANSCRIPTIONAL AND EPIGENETIC REPRESSIVE ENVIRONMENT IN BLOOD-FATED CELLS TO SUPPRESS ALTERNATIVE MESODERMAL LINEAGES

Porcher C. et al, (2016), EXPERIMENTAL HEMATOLOGY, 44, S46 - S46

zacitidine (AZA) Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes Compared with Conventional Care Regimens (CCR)

Doehner H. et al, (2016), BLOOD, 128

Vorinostat Does Not Improve Outcome in Patients with Acute Myeloid Leukemia and High Risk Myelodysplasia Treated with Azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial

Craddock C. et al, (2016), BLOOD, 128

CLONAL STRUCTURES OF LEUKAEMIA STEM CELL POPULATIONS IN MYELOID BLAST PHASE CHRONIC MYELOID LEUKAEMIA

Karamitros D. et al, (2016), HAEMATOLOGICA, 101, 234 - 235

NGS IDENTIFIES MUTATIONS PROGNOSTIC OF RELAPSE AFTER ALLO-SCT AND NOVEL CLONE EMERGENCE AT DISEASE RECURRENCE: IMPLICATIONS FOR STRATEGIES TO PREVENT POST ALLO-SCT RELAPSE

Quek L. et al, (2016), HAEMATOLOGICA, 101, 213 - 213

GENOME WIDE DYSREGULATION OF GENE EXPRESSION BY TRISOMY 21 IN FETAL LIVER HAEMATOPOIETIC STEM AND PROGENITOR CELLS

Roy A. et al, (2016), HAEMATOLOGICA, 101, 120 - 120

Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT

Craddock C. et al, (2016), BLOOD, 128

Early identification of Patients with Primary Refractory Acute Myeloid Leukaemia who Benefit from Allogeneic stem cell transplantation: an analysis of 8,907 patients from the uk ncrn aml working group

Craddock C. et al, (2016), BONE MARROW TRANSPLANTATION, 51, S5 - S5

Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders.

Gu Y. et al, (2015), Cochrane Database Syst Rev, 2015

Factors influencing success of clinical genome sequencing across a broad spectrum of disorders.

Taylor JC. et al, (2015), Nat Genet, 47, 717 - 726

n immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 low blasts.

Khan N. et al, (2015), Br J Haematol, 170, 80 - 84

n immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: Blood frequency of CD34+ CD38low blasts

Khan N. et al, (2015), British Journal of Haematology, 170, 80 - 84

Erratum to Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo, [Cancer Cell, 25, 2014, 794-808]

Woll PS. et al, (2015), Cancer Cell, 27, 603 - 605

Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia.

Bradbury C. et al, (2015), Leukemia, 29, 988 - 991

Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders.

Gu Y. et al, (2015), Cochrane Database Syst Rev, 3

Down syndrome preleukemia and leukemia.

Maloney KW. et al, (2015), Pediatr Clin North Am, 62, 121 - 137

Reprint of: Allogeneic hematopoietic cell transplantation for acute myeloid leukemia.

Vyas P. et al, (2015), Biol Blood Marrow Transplant, 21, S3 - 10

Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.

Gerstung M. et al, (2015), Nat Commun, 6

llogeneic hematopoietic cell transplantation for acute myeloid leukemia.

Vyas P. et al, (2015), Biol Blood Marrow Transplant, 21, 8 - 15

systematic review of the prenatal diagnosis and management of transient abnormal myelopoiesis

Tamblyn J. et al, (2015), BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 122, 55 - 56

COMPARISON OF A RESTRICTIVE VERSUS LIBERAL RED BLOOD CELL TRANSFUSION POLICY IN MYELODYSPLASTIC SYNDROMES AND OTHER BONE MARROW FAILURE DISORDERS - A SYSTEMATIC REVIEW

Gu Y. et al, (2015), LEUKEMIA RESEARCH, 39, S152 - S153

Down Syndrome Preleukemia and Leukemia

Maloney KW. et al, (2015), PEDIATRIC CLINICS OF NORTH AMERICA, 62, 121 - +

n Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy

Ferguson P. et al, (2015), BLOOD, 126

zacitidine: Duration of treatment used in routine clinical practice in patients with myelodysplastic syndromes (MDS) in England

Legg A. et al, (2015), BRITISH JOURNAL OF HAEMATOLOGY, 169, 79 - 79

Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee

Bejar R. et al, (2015), BLOOD, 126

Targeting HIF function: the debate continues.

Vyas P., (2014), Blood, 124, 3510 - 3511

Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.

Santini V. et al, (2014), Leuk Res, 38, 1381 - 1391

Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer.

Ju YS. et al, (2014), Elife, 3

Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.

Woll PS. et al, (2014), Cancer Cell, 25, 794 - 808

Erratum to Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo [Cancer Cell, 25 (2014) 794-808]

Woll PS. et al, (2014), Cancer Cell, 25

Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo

Woll PS. et al, (2014), Cancer Cell, 25, 794 - 808

GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia.

Maroz A. et al, (2014), Leukemia, 28, 1259 - 1270

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.

Guglielmelli P. et al, (2014), Blood, 123, 2157 - 2160

Guidelines for the diagnosis and management of adult myelodysplastic syndromes.

Killick SB. et al, (2014), Br J Haematol, 164, 503 - 525

Guidelines for the diagnosis and management of adult myelodysplastic syndromes

Killick SB. et al, (2014), British Journal of Haematology, 164, 503 - 525

GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia

Maroz A. et al, (2014), Leukemia, 28, 1259 - 1270

Myelodysplastic and Myeloproliferative diseases in children: Current concepts

Vyas P., (2014), Pediatric and Adolescent Medicine, 17, 81 - 97

Myelodysplastic and Myeloproliferative Diseases in Children: Current Concepts

Vyas P., (2014), 17, 81 - 97

Induction of a CD8+T Cell Response to Tumor Antigens Is Associated with Improved Survival in Patients Transplanted for Acute Myeloid Leukemia

Nagra S. et al, (2014), BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20, S156 - S156

COMPREHENSIVE ANALYSIS OF MUTATION STATUS, GENE EXPRESSION PROFILES, BLOOD AND BONE MARROW COUNTS AND OUTCOME IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

Pellagatti A. et al, (2014), HAEMATOLOGICA, 99, 234 - 234

10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN A SINGLE UK CENTRE: COMPARISON WITH PRE-TKI ERA AND EVALUATION OF 2013 ELN GUIDELINES

Khan D. et al, (2014), HAEMATOLOGICA, 99, 341 - 341

Cellular and Molecular Basis of Mutant Haemopoietic Transcription Factor GATA1s

Kelly S. et al, (2014), BLOOD, 124

Development and Evaluation of the Clinical Utility of a Next Generation Sequencing (NGS) Tool for Myeloid Disorders

Hamblin A. et al, (2014), BLOOD, 124

Clinical and Hematologic Impact of Fetal and Perinatal Variables on Mutant GATA1 Clone Size in Neonates with Down Syndrome

Bhatnagar N. et al, (2014), BLOOD, 124

Leukemia Stem Cell Potential of Different Progenitor Subpopulations in Myeloid Blast Phase CML

Kinstrie R. et al, (2014), BLOOD, 124

Functional and Genetic Heterogeneity of Distinct Leukemic Stem Cell Populations in CD34-Human Acute Myeloid Leukemia

Quek L. et al, (2014), BLOOD, 124

Molecular Detection of Minimal Residual Disease Provides the Most Powerful Independent Prognostic Factor Irrespective of Clonal Architecture in Nucleophosmin (NPM1) Mutant Acute Myeloid Leukemia

Ivey A. et al, (2014), BLOOD, 124

GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia.

Roberts I. et al, (2013), Blood, 122, 3908 - 3917

The impact of trisomy 21 on foetal haematopoiesis.

Roberts I. et al, (2013), Blood Cells Mol Dis, 51, 277 - 281

Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Papaemmanuil E. et al, (2013), Blood, 122, 3616 - 3627

cute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment.

Mussai F. et al, (2013), Blood, 122, 749 - 758

Structural basis for LMO2-driven recruitment of the SCL:E47bHLH heterodimer to hematopoietic-specific transcriptional targets.

El Omari K. et al, (2013), Cell Rep, 4, 135 - 147

Structural Basis for LMO2-Driven Recruitment of the SCL: E47bHLH Heterodimer to Hematopoietic-Specific Transcriptional Targets

ElOmari K. et al, (2013), Cell Reports, 4, 135 - 147

FLT3-ITDs instruct a myeloid differentiation and transformation bias in lymphomyeloid multipotent progenitors.

Mead AJ. et al, (2013), Cell Rep, 3, 1766 - 1776

Impact of isolated germline JAK2V617I mutation on human hematopoiesis.

Mead AJ. et al, (2013), Blood, 121, 4156 - 4165

zacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia.

Craddock C. et al, (2013), Leukemia, 27, 1028 - 1036

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.

Kuendgen A. et al, (2013), Leukemia, 27, 1072 - 1079

The impact of trisomy 21 on early human hematopoiesis.

Roy A. et al, (2013), Cell Cycle, 12, 533 - 534

Uncoupling VEGFA functions in arteriogenesis and hematopoietic stem cell specification.

Leung A. et al, (2013), Dev Cell, 24, 144 - 158

Uncoupling VEGFA Functions in Arteriogenesis and Hematopoietic Stem Cell Specification

Leung A. et al, (2013), Developmental Cell, 24, 144 - 158

Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities.

Dennis M. et al, (2013), Leuk Res Rep, 2, 70 - 74

Promoter hypermethylation

Pellacani D. et al, (2013), 43 - 72

COMBINED ANALYSES OF ROS, CELL CYCLE AND IMMUNOPHENOTYPE SHOWS THAT NORMAL HEMATOPOIETIC PROGENITOR SUBSETS HAVE A DIFFERENTIAL ROS PROFILE THAT IS LOST IN ACUTE MYELOID LEUKEMIA

Khan N. et al, (2013), HAEMATOLOGICA, 98, 12 - 12

Clinical and biological implications of gene mutations in MDS

Papaemmanuil E. et al, (2013), LEUKEMIA RESEARCH, 37, S9 - S9

ssociation Between Gene Expression Profiles and Commonly Mutated Genes In The Hematopoietic Stem Cells Of Patients With Myelodysplastic Syndromes

Pellagatti A. et al, (2013), BLOOD, 122

Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia.

Eyre T. et al, (2012), Blood, 120, 4441 - 4443

Residual Disease Detection by Flow Cytometry Predicts Risk of Relapse and Overall Survival in Patients with Acute Myeloid Leukemia Following Reduced Intensity- and Myeloablative-Allogeneic Hematopoietic Cell Transplantation

Bradbury CA. et al, (2012), BLOOD, 120

Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21.

Roy A. et al, (2012), Proc Natl Acad Sci U S A, 109, 17579 - 17584

Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia.

Jan M. et al, (2012), Sci Transl Med, 4

Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome.

Roy A. et al, (2012), Semin Fetal Neonatal Med, 17, 196 - 201

Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study.

Della Porta MG. et al, (2012), Haematologica, 97, 1209 - 1217

Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome

Roy A. et al, (2012), Seminars in Fetal and Neonatal Medicine, 17, 196 - 201

zacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).

Goodyear OC. et al, (2012), Blood, 119, 3361 - 3369

Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes.

Frisan E. et al, (2012), Blood, 119, 1532 - 1542

PERTURBATION OF FETAL LIVER HAEMATOPOIETIC STEM AND PROGENITOR CELL DEVELOPMENT BY TRISOMY 21

Roy A. et al, (2012), HAEMATOLOGICA, 97, 40 - 41

Residual Disease Detection by Flow Cytometry Predicts Risk of Relapse and Overall Survival in Patients with Acute Myeloid Leukemia Following Reduced Intensity- and Myeloablative- Allogeneic Hematopoietic Cell Transplantation

Bradbury CA. et al, (2012), BLOOD, 120

ZACITIDINE IS WELL TOLERATED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AND ITS ADMINISTRATION IS ASSOCIATED WITH A REDUCED RISK OF ACUTE GRAFT-VERSUS-HOST DISEASE

Craddock C. et al, (2012), HAEMATOLOGICA, 97, 21 - 22

High Throughput Targeted Gene Sequencing in 738 Myelodysplastic Syndromes Patients Reveals Novel Oncogenic Genes, Rare Driver Mutations and Complex Molecular Signatures with Potential Impact for Patient Diagnosis and Prognosis in the Clinic

Papaemmanuil E. et al, (2012), BLOOD, 120

Germline activating JAK2-mutation in a family with hereditary thrombocytosis

Mead A. et al, (2012), BRITISH JOURNAL OF HAEMATOLOGY, 157, 21 - 21

Enigmatic variation.

Roberts I. and Vyas P., (2011), Blood, 118, 6723 - 6724

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.

Papaemmanuil E. et al, (2011), N Engl J Med, 365, 1384 - 1395

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome.

Pellagatti A. et al, (2011), Br J Haematol, 155, 272 - 274

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome

Pellagatti A. et al, (2011), British Journal of Haematology, 155, 272 - 274

Methotrexate dose delivery is more important than ciclosporin level in graft-versus-host disease prophylaxis following T-replete reduced-intensity sibling allogeneic stem cell transplant.

Medd P. et al, (2011), Int J Hematol, 94, 266 - 278

nalysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia.

Alford KA. et al, (2011), Blood, 118, 2222 - 2238

Cardiac iron overload in transfusion-dependent patients with myelodysplastic syndromes.

Roy NBA. et al, (2011), Br J Haematol, 154, 521 - 524

c-Myb and GATA-1 alternate dominant roles during megakaryocyte differentiation.

García P. et al, (2011), J Thromb Haemost, 9, 1572 - 1581

c-Myb and GATA-1 alternate dominant roles during megakaryocyte differentiation

García P. et al, (2011), Journal of Thrombosis and Haemostasis, 9, 1572 - 1581

SCL-mediated regulation of the cell-cycle regulator p21 is critical for murine megakaryopoiesis.

Chagraoui H. et al, (2011), Blood, 118, 723 - 735

Generation of bivalent chromatin domains during cell fate decisions.

De Gobbi M. et al, (2011), Epigenetics Chromatin, 4

Clever leukemic stem cells branch out.

Vyas P. and Jacobsen SEW., (2011), Cell Stem Cell, 8, 242 - 244

Structure of the leukemia oncogene LMO2: implications for the assembly of a hematopoietic transcription factor complex.

El Omari K. et al, (2011), Blood, 117, 2146 - 2156

Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia.

Goardon N. et al, (2011), Cancer Cell, 19, 138 - 152

Development of real-time quantitative polymerase chain reaction assays to track treatment response in retinoid resistant acute promyelocytic leukemia.

Jovanovic JV. et al, (2011), Front Oncol, 1

Methotrexate dose delivery is more important than ciclosporin level in graft-versus-host disease prophylaxis following T-replete reduced-intensity sibling allogeneic stem cell transplant

Medd P. et al, (2011), International Journal of Hematology, 1 - 13

Quantitation of Leukemic Stem Cell Populations Predicts Clinical Outcome in Acute Myeloid Leukaemia

Craddock CF. et al, (2011), BLOOD, 118, 292 - 292

Somatic Mutation of SF3B1, a Gene Encoding a Core Component of RNA Splicing Machinery, in Myelodysplasia with Ring Sideroblasts

Malcovati L. et al, (2011), BLOOD, 118, 3 - 4

Shared care protocol for the management of essential thrombocythaemia patients in primary care

Sweeney C. et al, (2011), BRITISH JOURNAL OF HAEMATOLOGY, 153, 55 - 55

MULTICENTRE VALIDATION OF A REPRODUCIBLE FLOW CYTOMETRIC SCORE FOR THE DIAGNOSIS OF LOWRISK MYELODYSPLASTIC SYNDROMES: RESULTS OF A EUROPEAN LeukemiaNET STUDY

Picone C. et al, (2011), CYTOMETRY PART A, 79A, 1051 - 1052

Germline Activating JAK2 V617I Mutation, in a Family with Hereditary Thrombocytosis

Mead AJ. et al, (2011), BLOOD, 118, 758 - 759

zacitidine Induces Expansion of Regulatory T Cells and Tumour Specific CD8+T Lymphocytes After Allogeneic Stem Cell Transplantation: A Strategy for Epigenetic Manipulation of a Graft-Versus-Leukemia Response

Dennis M. et al, (2011), BLOOD, 118, 152 - 152

Cold-adapted and rhizosphere-competent strain of Rahnella sp. with broad-spectrum plant growth-promotion potential.

Vyas P. et al, (2010), J Microbiol Biotechnol, 20, 1724 - 1734

Trilineage Perturbation of Hematopoiesis In Neonates with Down Syndrome

Norton A. et al, (2010), BLOOD, 116, 384 - 384

VEGFA Controls Haematopoietic Stem Cell Specification In a Dose Dependent, Isoform Specific Manner

Leung A. et al, (2010), BLOOD, 116, 181 - 181

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells

Pellagatti A. et al, (2010), BLOOD, 116, 135 - 135

Co Existence of LMPP Like and GMP Like Leukemia Stem Cells In Acute Myeloid Leukemia

Goardon N. et al, (2010), BLOOD, 116, 46 - 46

GATA1 Mutation In Transient Leukemia (TL) and Myeloid Leukemia of Down Syndrome

Reinhardt K. et al, (2010), BLOOD, 116, 722 - 722

Regulation of Gata1 Expression by HS+3 5

Draper JE. et al, (2010), BLOOD, 116, 1580 - 1580

Trilineage Perturbation of Hematopoiesis In Neonates with Down Syndrome

Norton A. et al, (2010), BLOOD, 116, 384 - 384

VEGFA Controls Haematopoietic Stem Cell Specification In a Dose Dependent, Isoform Specific Manner

Leung A. et al, (2010), BLOOD, 116, 181 - 181

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells

Pellagatti A. et al, (2010), BLOOD, 116, 135 - 135

Co Existence of LMPP Like and GMP Like Leukemia Stem Cells In Acute Myeloid Leukemia

Goardon N. et al, (2010), BLOOD, 116, 46 - 46

ssessment of minimal residual disease in acute myeloid leukemia.

Grimwade D. et al, (2010), Curr Opin Oncol, 22, 656 - 663

Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.

Goodyear O. et al, (2010), Blood, 116, 1908 - 1918

Persistent malignant stem cells in del(5q) myelodysplasia in remission.

Tehranchi R. et al, (2010), N Engl J Med, 363, 1025 - 1037

Genome-wide identification of TAL1's functional targets: insights into its mechanisms of action in primary erythroid cells.

Kassouf MT. et al, (2010), Genome Res, 20, 1064 - 1083

Measurement of utility values in the UK for health states related to immune thrombocytopenic purpura.

Szende A. et al, (2010), Curr Med Res Opin, 26, 1893 - 1903

FACTORS DETERMINING CLINICAL RESPONSE TO 5 '-AZACITDINE AND SODIUM VALPROATE COMBINATION THERAPY IN PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASIA

Craddock C. et al, (2010), HAEMATOLOGICA, 95, 225 - 225

INDUCTION OF A CD8(+) T CELL RESPONSE TO THE MAGE CANCER TESTIS ANTIGEN BY COMBINED TREATMENT WITH AZACITIDINE AND SODIUM VALPROATE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASIA

Goodyear O. et al, (2010), HAEMATOLOGICA, 95, 14 - 14

PLATELET DYSFUNCTION AND MDS FEATURES DUE TO NOVEL SOMATIC GATA1 MUTATION

Freson K. et al, (2010), HAEMATOLOGICA, 95, 217 - 217

Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia.

Craddock C. et al, (2010), Haematologica, 95, 989 - 995

Lineage-specific combinatorial action of enhancers regulates mouse erythroid Gata1 expression.

Drissen R. et al, (2010), Blood, 115, 3463 - 3471

cute leukemias in children with Down syndrome.

Zwaan CM. et al, (2010), Hematol Oncol Clin North Am, 24, 19 - 34

Classic and overlap chronic graft-versus-host disease after T-replete reduced intensity conditioned sibling allograft usually starts within a year, causes prolonged morbidity but low mortality and is influenced by prophylactic methotrexate and ciclosporin dosing

Medd PG. et al, (2010), BRITISH JOURNAL OF HAEMATOLOGY, 149, 69 - 69

Regulation of Gata1 Expression by HS+3.5

Draper JE. et al, (2010), BLOOD, 116, 1580 - 1580

GATA1 Mutation In Transient Leukemia (TL) and Myeloid Leukemia of Down Syndrome

Reinhardt K. et al, (2010), BLOOD, 116, 722 - 722

Trilineage Perturbation of Hematopoiesis In Neonates with Down Syndrome

Norton A. et al, (2010), BLOOD, 116, 384 - 384

VEGFA Controls Haematopoietic Stem Cell Specification In a Dose-Dependent, Isoform-Specific Manner

Leung A. et al, (2010), BLOOD, 116, 181 - 181

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells

Pellagatti A. et al, (2010), BLOOD, 116, 135 - 135

Co-Existence of LMPP-Like and GMP-Like Leukemia Stem Cells In Acute Myeloid Leukemia

Goardon N. et al, (2010), BLOOD, 116, 46 - 46

BONE MARROW HAEMATOPOIESIS IN THE SECOND TRIMESTER OF FETAL LIFE IS STRONGLY BIASED TOWARDS B-LYMPHOPOIESIS AND IS SEVERELY IMPAIRED AT THE EBP-CBP TRANSITION IN DOWN SYNDROME

Roy A. et al, (2010), HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95, 91 - 91

FACTORS DETERMINING CLINICAL RESPONSE TO 5′-AZACITDINE AND SODIUM VALPROATE COMBINATION THERAPY IN PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASIA

Craddock C. et al, (2010), HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95, 225 - 225

PLATELET DYSFUNCTION AND MDS FEATURES DUE TO NOVEL SOMATIC GATA1 MUTATION

Freson K. et al, (2010), HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95, 217 - 217

INDUCTION OF A CDS+ T CELL RESPONSE TO THE MAGE CANCER TESTIS ANTIGEN BY COMBINED TREATMENT WITH AZACITIDINE AND SODIUM VALPROATE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASIA

Goodyear O. et al, (2010), HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95, 14 - 14

NIH consensus chronic GvHD following T-replete reduced-intensity conditioning sibling allograft usually develops within a year, causes prolonged morbidity but low mortality and is influenced by prophylactic methotrexate dose

Medd PG. et al, (2010), BONE MARROW TRANSPLANTATION, 45, S138 - S139

nalysis of factors affecting outcome in recipients of bone marrow transplantation for myelodysplasia; a single centre's experience over a nine year period

Stoll VM. et al, (2010), BRITISH JOURNAL OF HAEMATOLOGY, 149, 81 - 82

cute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.

Roy A. et al, (2009), Br J Haematol, 147, 3 - 12

Molecular targeting of cancer stem cells.

Gupta R. et al, (2009), Cell Stem Cell, 5, 125 - 126

Color Atlas of Clinical Hematology

Hoffbrand AV. et al, (2009)

Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.

van de Loosdrecht AA. et al, (2009), Haematologica, 94, 1124 - 1134

Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes.

Goardon N. et al, (2009), Haematologica, 94, 1160 - 1163

5 ' AZACITIDINE IN COMBINATION WITH VALPROIC ACID INDUCES COMPLETE REMISSIONS IN PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKAEMIA BUT DOES NOT ERADICATE CLONAL LEUKAEMIC STEM/PROGENITOR CELLS

Craddock C. et al, (2009), HAEMATOLOGICA, 94, 429 - 429

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Fenaux P. et al, (2009), Lancet Oncol, 10, 223 - 232

5′ AZACITIDINE IN COMBINATION WITH VALPROIC ACID INDUCES COMPLETE REMISSIONS IN PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKAEMIA BUT DOES NOT ERADICATE CLONAL LEUKAEMIC STEM/PROGENITOR CELLS

Craddock C. et al, (2009), HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 94, 429 - 429

MEASUREMENT OF HEALTH UTILITY VALUES IN THE UK FOR HEALTH STATES RELATED TO IMMUNE (IDIOPATHIC) THROMBOCYTOPENIC PURPURA (ITP)

Szende A. et al, (2009), VALUE IN HEALTH, 12, A383 - A383

GATA-2 regulates granulocyte-macrophage progenitor cell function.

Rodrigues NP. et al, (2008), Blood, 112, 4862 - 4873

bnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations.

Tunstall-Pedoe O. et al, (2008), Blood, 112, 4507 - 4511

Good news for the aging population?

Vyas P. and Higgs DR., (2008), Blood, 112

Characterization of megakaryocyte GATA1-interacting proteins: the corepressor ETO2 and GATA1 interact to regulate terminal megakaryocyte maturation.

Hamlett I. et al, (2008), Blood, 112, 2738 - 2749

Differential use of SCL/TAL-1 DNA-binding domain in developmental hematopoiesis.

Kassouf MT. et al, (2008), Blood, 112, 1056 - 1067

Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML.

Hasle H. et al, (2008), Leukemia, 22, 1428 - 1430

Cerebral venous sinus thrombosis in polycythaemia.

Thomson D. et al, (2008), Br J Hosp Med (Lond), 69

Response: JAK mutations in Down syndrome-associated transient myeloproliferative disorder and acute megakaryocytic leukemia

Vyas P. and Crispino J., (2008), Blood, 111

cute leukemias in children with Down syndrome.

Zwaan MC. et al, (2008), Pediatr Clin North Am, 55, 53 - x

Myelodysplastic Syndrome Associated with a Clonal GATA1 Mutation.

Freson K. et al, (2008), BLOOD, 112, 451 - 452

GATA-2 Regulates Granulocyte-Macrophage Progenitor Cell Function.

Rodrioues NP. et al, (2008), BLOOD, 112, 503 - 503

Reduced CD38 Expression on CD34+Cells as a Diagnostic Test in Myelodysplastic Syndromes.

Vyas P. et al, (2008), BLOOD, 112, 922 - 923

Sweet's syndrome and neutrophilic panniculitis associated with G-CSF treatment in a patient with myelodysplasia

Brown V. et al, (2008), BRITISH JOURNAL OF DERMATOLOGY, 159, 99 - 99

5′ Azacitidine in Combination with Valproic Acid Induces Complete Remissions in Patients with Advanced Acute Myeloid Leukaemia but Does Not Eradicate Clonal Leukaemic Stem/Progenitor Cells.

Craddock C. et al, (2008), BLOOD, 112, 348 - 349

Haematology of Down syndrome.

Webb D. et al, (2007), Arch Dis Child Fetal Neonatal Ed, 92, F503 - F507

nalysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome.

Norton A. et al, (2007), Blood, 110, 1077 - 1079

Severe TMD/AMKL with GATA1 mutation in a stillborn fetus with Down syndrome.

Heald B. et al, (2007), Nat Clin Pract Oncol, 4, 433 - 438

GATA1 mutational analysis in chronic myeloid leukaemia.

Halsey C. et al, (2007), Br J Haematol, 137, 375 - 376

Molecular insights into Down syndrome-associated leukemia.

Vyas P. and Crispino JD., (2007), Curr Opin Pediatr, 19, 9 - 14

Endoplasmic reticulum gene expression profile of erythroid progenitors in low risk myelodysplastic syndromes

Gyan E. et al, (2007), LEUKEMIA RESEARCH, 31, S78 - S79

Transcriptional regulation of GATA1

Drissen R. et al, (2007), BLOOD CELLS MOLECULES AND DISEASES, 38, 186 - 187

Endoplasmic reticulum gene expression profile of erythroid progenitors in low risk myelodysplastic syndromes

Gyan EG. et al, (2007), HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 92, 84 - 84

cute megakaryoblastic leukaemia in Down syndrome and non-Down syndrome patients - molecular signature of a disease - subtypes with distinct treatment outcomes

Vyas P. et al, (2007), EJC SUPPLEMENTS, 5, 36 - 36

Cross-talk between c-Myb and GATA-1 regulates the entry into megakaryocyte differentiation

Berlanga O. et al, (2007), BLOOD, 110, 371A - 371A

Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis.

Vyas P. and Roberts I., (2006), Early Hum Dev, 82, 767 - 773

Linkage and mutational analysis of the CDAN1 gene reveals genetic heterogeneity in congenital dyserythropoietic anemia type I.

Ahmed MR. et al, (2006), Blood, 107, 4968 - 4969

Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors.

Purbhoo MA. et al, (2006), J Immunol, 176, 7308 - 7316

Characterization of a megakaryocyte-specific enhancer of the key hemopoietic transcription factor GATA1.

Guyot B. et al, (2006), J Biol Chem, 281, 13733 - 13742

Evidence of genetic heterogeneity in congenital dyserythropoietic anaemia type I.

Ahmed MR. et al, (2006), Br J Haematol, 133, 444 - 445

Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling.

Bourquin J-P. et al, (2006), Proc Natl Acad Sci U S A, 103, 3339 - 3344

Characterization of the hemopoietic defect in early stages of the myelodysplastic syndromes.

Vyas P. and Sternberg A., (2006), Adv Enzyme Regul, 46, 98 - 112

Characterisation erythroid-specific cis-elements regulating the key transcription factor GATA1.

Drissen R. et al, (2006), BLOOD, 108, 344A - 345A

Trisomy 21 expands the megakaryocyte-erythroid progenitor compartment in human fetal liver-implications for down syndrome AMKL.

Tunstall-Pedoe O. et al, (2006), BLOOD, 108, 170A - 170A

nalysis of GATA-1 mutations in chronic myeloid leukaemia.

Halsey C. et al, (2006), BLOOD, 108, 276B - 276B

ETO-2 associates with SCL in erythroid cells and megakaryocytes and provides repressor functions in erythropoiesis.

Schuh AH. et al, (2005), Mol Cell Biol, 25, 10235 - 10250

Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome.

Sternberg A. et al, (2005), Blood, 106, 2982 - 2991

GATA1-mediated megakaryocyte differentiation and growth control can be uncoupled and mapped to different domains in GATA1.

Kuhl C. et al, (2005), Mol Cell Biol, 25, 8592 - 8606

Haploinsufficiency of GATA-2 perturbs adult hematopoietic stem-cell homeostasis.

Rodrigues NP. et al, (2005), Blood, 106, 477 - 484

GATA-1 forms distinct activating and repressive complexes in erythroid cells.

Rodriguez P. et al, (2005), EMBO J, 24, 2354 - 2366

GATA1 mutation analysis demonstrates two distinct primary leukemias in a child with down syndrome; implications for leukemogenesis.

Hellebostad M. et al, (2005), J Pediatr Hematol Oncol, 27, 408 - 409

Selective impairment of platelet activation to collagen in the absence of GATA1.

Hughan SC. et al, (2005), Blood, 105, 4369 - 4376

GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder.

Carpenter E. et al, (2005), Br J Haematol, 128, 548 - 551

Characterisation of SCL DNA-binding functions in vivo in haematopoiesis.

Kassouf M. et al, (2005), BLOOD, 106, 493A - 493A

The bHLH protein SCL/Tal-l interacts with the co-repressor ETO-2 in erythroid cells and megakaryocytes.

Schuh A. et al, (2005), BLOOD CELLS MOLECULES AND DISEASES, 34, 118 - 118

Characterisation of distinct GATA-1 complexes in erythroid cells reveals a major role in gene repression.

Rodriguez P. et al, (2005), BLOOD CELLS MOLECULES AND DISEASES, 34, 118 - 119

Characterization of distinct GATA-1 complexes in erythroid cells.

Rodriguez P. et al, (2005), BLOOD CELLS MOLECULES AND DISEASES, 34, 124 - 124

GATA1-mediated megakaryocyte differentiation and growth control can be uncoupled and mapped to different domains in GATA1

Kuhl C. et al, (2005), BLOOD, 106, 244A - 244A

Characterization of a megakaryocyte-specific enhancer of the key hemopoietic transcription factor GATA1

Guyot B. et al, (2005), BLOOD, 106, 245A - 245A

Differences in the chromatin structure and cis-element organization of the human and mouse GATA1 loci: implications for cis-element identification.

Valverde-Garduno V. et al, (2004), Blood, 104, 3106 - 3116

bsence of mutations in the key megakaryocyte transcriptional regulator FOG-1 in patients with idiopathic myelofibrosis.

Fisher C. et al, (2004), Br J Haematol, 126, 750 - 752

Decoding hematopoietic specificity in the helix-loop-helix domain of the transcription factor SCL/Tal-1.

Schlaeger TM. et al, (2004), Mol Cell Biol, 24, 7491 - 7502

Deletion of the major GATA1 enhancer HS 1 does not affect eosinophil GATA1 expression and eosinophil differentiation.

Guyot B. et al, (2004), Blood, 104, 89 - 91

Natural history of GATA1 mutations in Down syndrome.

Ahmed M. et al, (2004), Blood, 103, 2480 - 2489

Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome.

Gurbuxani S. et al, (2004), Blood, 103, 399 - 406

Myelodysplastic syndrome due to somatic GATA1 mutation.

Freson K. et al, (2004), BLOOD, 104, 262B - 262B

GATA-1 forms distinct activating and repressive complexes in erythroid cells

Strouboulis J. et al, (2004), BLOOD, 104, 105A - 105A

Lineage-specific transcriptional regulation of GATA1 is dependent on lineage-specific utilisation of multiple cis-elements and haematopoietic transcription factors.

Vyas P. et al, (2004), BLOOD, 104, 448A - 448A

The oncoprotein SCL/Tal-1 associates with the co-repressor ETO-2 in multiprotein complexes in erythroid cells and megalkaryocytes.

Schuh AH. et al, (2004), BLOOD, 104, 759A - 759A

Purification and characterization of chitinase from Alcaligenes xylosoxydans.

Vaidya R. et al, (2003), Biotechnol Lett, 25, 715 - 717

The novel method for isolating chitinolytic bacteria and its application in screening for hyperchitinase producing mutant of Alcaligenes xylosoxydans.

Vaidya RJ. et al, (2003), Lett Appl Microbiol, 36, 129 - 134

Stem cells deficient in p21Cip1/Waf1 compete poorly in establishing long-term bone marrow hematopoiesis.

Rodrigues NP. et al, (2003), BLOOD, 102, 570A - 570A

Oligonucleotide microarray analysis of CD34+cells in patients with low risk myelodysplasia and age-matched healthy subjects.

Sternberg A. et al, (2003), BLOOD, 102, 912A - 912A

Characterisation and comparison of the human and mouse GATA-1 transcriptional domain.

Vyas P. et al, (2003), BLOOD, 102, 573A - 573A

Haploinsufficiency of GAtA-2 effects adult stem cell homeostasis.

Rodrigues NP. et al, (2003), BLOOD, 102, 565A - 565A

Mutational analysis of the CDAN1 gene in familial and sporadic congenital dyserythropoietic anaemia type 1

Ahmed MR. et al, (2003), BLOOD, 102, 160A - 160A

Natural history of GATA-1 mutations in Down syndrome.

Ahmed M. et al, (2003), BLOOD, 102, 139A - 139A

Identification of critical residues for the function of the bHLH transcription factor SCL in hematopoietic stem cells.

Porcher C. et al, (2003), BLOOD, 102, 131A - 131A

Transcriptional regulation of FOG-1

Hayes S. et al, (2003), BLOOD CELLS MOLECULES AND DISEASES, 31, 146 - 146

Stem cells deficient in p21Cip1/Waf1 compete poorly in establishing long-term bone marrow hematopoiesis.

Rodrigues NP. et al, (2002), BLOOD, 100, 294A - 294A

Pathology and genetics: Tumours of haematopoietic and lymphoid tissues

Vyas P., (2001), Lancet Oncology, 2

Inositol polyphosphate 4-phosphatase type I regulates cell growth downstream of transcription factor GATA-1.

Vyas P. et al, (2000), Proc Natl Acad Sci U S A, 97, 13696 - 13701

Different sequence requirements for expression in erythroid and megakaryocytic cells within a regulatory element upstream of the GATA-1 gene.

Vyas P. et al, (1999), Development, 126, 2799 - 2811

Consequences of GATA-1 deficiency in megakaryocytes and platelets.

Vyas P. et al, (1999), Blood, 93, 2867 - 2875

Early PCR-negativity after allogeneic BMT in adults with t(4;11) ALL in the absence of acute or chronic GVHD.

D'Sa S. et al, (1999), Bone Marrow Transplant, 23, 695 - 696

Mrvi1, a common MRV integration site in BXH2 myeloid leukemias, encodes a protein with homology to a lymphoid-restricted membrane protein Jaw1.

Shaughnessy JD. et al, (1999), Oncogene, 18, 2069 - 2084

Type 1 inositol polyphosphate-4-phosphatase influences growth of primary megakaryocytes and other cell types and is differentially expressed in the absence of GATA-1.

Vyas P. et al, (1999), BLOOD, 94, 685A - 685A

Mice lacking transcription factor NF-E2 provide in vivo validation of the proplatelet model of thrombocytopoiesis and show a platelet production defect that is intrinsic to megakaryocytes.

Lecine P. et al, (1998), Blood, 92, 1608 - 1616

Consequences of GATA-1 deficiency in megakaryocytes and platelets.

Vyas P. et al, (1998), BLOOD, 92, 195A - 195A

n H∞ system identification algorithm applied to Tokamak modelling

Coutlis A. et al, (1997), PROCEEDINGS OF THE 36TH IEEE CONFERENCE ON DECISION AND CONTROL, VOLS 1-5, 3685 - 3690

Successful long-term treatment with porcine factor VIII of a patient with haemophilia A and an inhibitor to factor VIII.

Vyas P. et al, (1996), Haemophilia, 2, 240 - 243

Conservation of position and sequence of a novel, widely expressed gene containing the major human alpha-globin regulatory element.

Vyas P. et al, (1995), Genomics, 29, 679 - 689

The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase.

Amin AR. et al, (1995), Proc Natl Acad Sci U S A, 92, 7926 - 7930

Contrasting effects of alpha and beta globin regulatory elements on chromatin structure may be related to their different chromosomal environments.

Craddock CF. et al, (1995), EMBO J, 14, 1718 - 1726

Bone marrow transplantation. Review articles must accurately reflect current practice.

Rule SA. et al, (1995), BMJ, 310

Maple syrup urine disease--2-4 DPNH test as a routine in highly sick newborns.

Mangal N. et al, (1994), Indian Pediatr, 31, 1440 - 1441

nalysis of the human alpha-globin gene cluster in transgenic mice.

Sharpe JA. et al, (1993), Proc Natl Acad Sci U S A, 90, 11262 - 11266

Role of upstream DNase I hypersensitive sites in the regulation of human alpha globin gene expression.

Sharpe JA. et al, (1993), Blood, 82, 1666 - 1671

Structure of the human 3-methyladenine DNA glycosylase gene and localization close to the 16p telomere.

Vickers MA. et al, (1993), Proc Natl Acad Sci U S A, 90, 3437 - 3441

Characterization of the telomeric region of human chromosome 16p

Higgs DR. et al, (1993), Chromosomes Today, 11, 35 - 47

Regulation of human embryonic globin genes zeta 2 and epsilon in stably transformed mouse erythroleukemia cells.

Vyas P. et al, (1992), Blood, 80, 1832 - 1837

Cis-acting sequences regulating expression of the human alpha-globin cluster lie within constitutively open chromatin.

Vyas P. et al, (1992), Cell, 69, 781 - 793

THE STRUCTURE AND FUNCTION OF CIS-ACTING REGULATORY SEQUENCES UPSTREAM OF THE HUMAN ALPHA-GLOBIN GENE-COMPLEX

HIGGS DR. et al, (1991), REGULATION OF HEMOGLOBIN SWITCHING, 194 - 204

Bone marrow transplantation.

Vyas P. and Goldstone AH., (1990), Practitioner, 234, 732 - 734

The alpha-thalassemias.

Higgs DR. et al, (1990), Ann N Y Acad Sci, 612, 15 - 22

Scabies Infestation following Autologous Bone Marrow Transplantation.

Vyas P. et al, (1990), Leuk Lymphoma, 3, 73 - 74

THE ALPHA-THALASSEMIAS

HIGGS DR. et al, (1990), ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 612, 15 - 22

The interaction of alpha thalassaemia and sickle cell-beta zero thalassaemia.

Vyas P. et al, (1988), Br J Haematol, 70, 449 - 454

Cookies on this website

Contact information

Research groups

Websites

Research Projects Available

Paresh Vyas

Biography

Recent publications